These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35241398)

  • 1. Quantifying the contribution of lipoprotein(a) to all apoB containing particles.
    Chilazi M; Zheng W; Park J; Marvel FA; Khoury S; Jones SR; Martin SS
    J Clin Lipidol; 2022; 16(2):220-226. PubMed ID: 35241398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk.
    Rehman MB; Tudrej BV
    Lipids Health Dis; 2024 Sep; 23(1):316. PubMed ID: 39334349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.
    Marston NA; Giugliano RP; Melloni GEM; Park JG; Morrill V; Blazing MA; Ference B; Stein E; Stroes ES; Braunwald E; Ellinor PT; Lubitz SA; Ruff CT; Sabatine MS
    JAMA Cardiol; 2022 Mar; 7(3):250-256. PubMed ID: 34773460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and partial characterization of discrete apolipoprotein B containing lipoprotein particles produced by human hepatoma cell line HepG2.
    Dashti N; Alaupovic P; Knight-Gibson C; Koren E
    Biochemistry; 1987 Jul; 26(15):4837-46. PubMed ID: 2822101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk.
    Glavinovic T; Thanassoulis G; de Graaf J; Couture P; Hegele RA; Sniderman AD
    J Am Heart Assoc; 2022 Oct; 11(20):e025858. PubMed ID: 36216435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance between lipoprotein (a) and LDL-cholesterol levels in cardiovascular risk assessment in apparently healthy subjects.
    Bergmann K; Stefanska A; Krintus M; Sypniewska G
    Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1429-1436. PubMed ID: 37169665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ELISA quantitation of apolipoproteins in plasma lipoprotein fractions: ApoE in ApoB-containing lipoproteins (Lp B:E) and ApoB in ApoE-containing lipoproteins (Lp E:B).
    Yang CY; Xie YH; Yang M; Quion JA; Gotto AM
    J Protein Chem; 1995 Oct; 14(7):503-9. PubMed ID: 8561846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis.
    Björnson E; Adiels M; Taskinen MR; Burgess S; Chapman MJ; Packard CJ; Borén J
    J Am Coll Cardiol; 2024 Jan; 83(3):385-395. PubMed ID: 38233012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment.
    Galimberti F; Casula M; Olmastroni E
    Pharmacol Res; 2023 Sep; 195():106873. PubMed ID: 37517561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein cholesterol-to-apolipoprotein B ratio as a potential indicator of LDL particle size and plasma atherogenicity in type 2 diabetes.
    Viktorinova A; Malickova D; Svitekova K; Choudhury S; Krizko M
    Diabetes Res Clin Pract; 2021 Jun; 176():108858. PubMed ID: 34015391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM.
    Langlois MR; Nordestgaard BG; Langsted A; Chapman MJ; Aakre KM; Baum H; Borén J; Bruckert E; Catapano A; Cobbaert C; Collinson P; Descamps OS; Duff CJ; von Eckardstein A; Hammerer-Lercher A; Kamstrup PR; Kolovou G; Kronenberg F; Mora S; Pulkki K; Remaley AT; Rifai N; Ros E; Stankovic S; Stavljenic-Rukavina A; Sypniewska G; Watts GF; Wiklund O; Laitinen P;
    Clin Chem Lab Med; 2020 Mar; 58(4):496-517. PubMed ID: 31855562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of thyroid hormone on plasma apolipoproteins and apoA- and apoB-containing lipoprotein particles.
    Liu XQ; Rahman A; Bagdade JD; Alaupovic P; Kannan CR
    Eur J Clin Invest; 1998 Apr; 28(4):266-70. PubMed ID: 9615901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
    Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.
    Enkhmaa B; Anuurad E; Zhang W; Berglund L
    Atherosclerosis; 2014 Jul; 235(1):223-9. PubMed ID: 24859635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis.
    Siamopoulos KC; Elisaf MS; Bairaktari HT; Pappas MB; Sferopoulos GD; Nikolakakis NG
    Perit Dial Int; 1995; 15(8):342-7. PubMed ID: 8785232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Lp-PLA(2) mass and apoB-lipoproteins that carry Lp-PLA(2) decrease after sodium.
    Constantinides A; Kerstens MN; Dikkeschei BD; van Pelt LJ; Tellis CC; Tselepis AD; Dullaart RP
    Eur J Clin Invest; 2012 Nov; 42(11):1235-43. PubMed ID: 22957745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with hyperthyroidism.
    Klausen IC; Hegedüs L; Hansen PS; Nielsen FE; Gerdes LU; Faergeman O
    J Mol Med (Berl); 1995 Jan; 73(1):41-6. PubMed ID: 7633941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein (a) concentrations in patients with various dyslipidaemias.
    Elisaf MS; Bairaktari ET; Tzallas CS; Siamopoulos KC
    Ann Med; 1997 Aug; 29(4):305-9. PubMed ID: 9375987
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.